Relmada Therapeutics, Inc. (RLMD) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Relmada Therapeutics, Inc. (RLMD) closed at USD 3.20 on 2026-10-15, a change of +30.6 % over the past year, with a market capitalization of USD 330.68M.

Relmada Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Relmada Therapeutics, Inc. key figures

Previous close

USD 3.20 (2026-10-15)

1-year change

+30.6 %

Market cap

USD 330.68M

Enterprise value

USD 112.95M

P/E ratio (trailing)

-3.41

P/E ratio (forward)

-7.56

EPS (trailing)

-0.91

EPS (forward)

-0.41

PEG ratio

n/a

Price to book

1.60

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.55

Employees

17

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Relmada Therapeutics, Inc. and compare it with other stocks.